US EditionPublished • loading... • Updated
Semaglutide Lowers SGA-Related Cardiometabolic Risk
Summary by Anti-Aging, Acupuncture and Health News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Semaglutide Lowers SGA-Related Cardiometabolic Risk
Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk in individuals with schizophrenia spectrum disorders compared with placebo. Medscape Medical News Source link : https://www.medscape.com/viewarticle/semaglutide-lowers-antipsychotic-related-cardiometabolic-2025a1000yxa?src=rss Author : Publish date : 2025-12-12 13:00:00 Copyright for syndicated content belongs to the linke…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
